News – Page 1090 – Endpoints News

Spark Therapeutics faces a grilling as FDA ponders a pioneering OK for gene therapy

8 years ago

Abbas Hussain swings from top GSK pharma post to powerhouse Chinese private equity player C-Bridge

8 years ago

Biotech scientist/entrepreneur Saurabh Saha makes an unusual return to the arms of a big — and excessively discreet ...

8 years ago

Third Rock-backed Allena looks to springboard a $92M IPO off of a failed PhIIb

8 years ago

Flexion nabs FDA OK for its potential blockbuster osteoarthritis drug, triggering new buyout buzz

8 years ago

AstraZeneca’s next big cancer drug linked to falsified preclinical data; Harmony raises $270M, nabs development ...

8 years ago

David Meeker starts a new biotech chapter in his career; Sam Kulkarni takes the helm at CRISPR

8 years ago

Third Rock, SV bankroll another PhI/II for a new, improved and jab-free wet AMD drug

8 years ago

'Going big': Merck launches frontline PhIII lung cancer study for Keytruda/Yervoy combo

8 years ago

Facing an exodus, EMA starts to line up temp replacements as top staffers jump ship

8 years ago

In a setback, Bayer, J&J say their big PhIII secondary stroke trial for Xarelto failed

8 years ago

Allergan shows how you can destroy your rep and get mobbed by lawmakers in 4 easy steps

8 years ago

We've taken a big step forward at Endpoints News — and with your help, we'll make more strides

8 years ago

Sanofi/Regeneron win a new trial on Praluent patents; BridgeBio bankrolls $30M biotech startup

8 years ago

Acadia adopts a new PhIII game plan for 'breakthrough' med, dumps Alzheimer's PhII

8 years ago

Facebook billionaires Peter Thiel and Sean Parker backing a stealth immunotherapy biotech — report

8 years ago

Bluebird’s gene therapy shows promise in keeping lethal Lorenzo’s Oil disease in check

8 years ago

Armed with a $47M round, Gates-backed Visterra aims at a PhIIb flu drug study

8 years ago

Faster, pricier and often worthless: Study slams regulators for wave of questionable cancer drug OKs

8 years ago

Rhythm Pharma IPO goes over the top, snags $120M in latest sign the biotech window is wide open

8 years ago

Congress fires another salvo at Allergan’s Mohawk deal; AI outfit raises $60M for discovery effort

8 years ago

FDA offers surprise OK for Mylan’s Copaxone knockoffs, slamming Teva

8 years ago

What failure? Catabasis shares soar after execs tout open-label data, PhIII plans

8 years ago

Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round

8 years ago

First page Previous page 1087 1088 108910901091 1092 1093 Next page Last page